# Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension

> **NCT06987097** · NA · NOT_YET_RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 410 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06987097
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2028-02-28
- **Final completion:** 2029-03-01
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987097, "Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06987097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*